Delivery Order SPE2DB20D1100-SPE2DB25FD9G1
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,214.62 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mls, a injectable medication used to treat autoimmune conditions. The contract, issued on July 30, 2025, is a firm fixed price delivery order with an ultimate completion date of July 31, 2025. The award carries no set-aside designation and represents a competitively awarded transaction. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,147.29 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen for Crohn's disease and ulcerative colitis treatment at an 80-milligram dose strength. This firm fixed-price delivery order, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, was competitively awarded without set-aside designation. The product will be delivered to the Conshohocken, Pennsylvania location, which serves as...
- The Defense Logistics Agency awarded a $7,022.45 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-competitive delivery order is issued under a firm fixed-price arrangement and represents a single pharmaceutical supply transaction sourced from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. HUMIRA is a widely prescribed biologic immunosuppressant used to...
- The Defense Logistics Agency awarded a delivery order valued at $5,485.29 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen injections, 40 mg/0.4 mL. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 31, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic medication prescribed for autoimmune conditions including...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HUMIRA Pen 40mg/4mL (2 pens) with a ceiling value of $26,615.29. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. HUMIRA...
- The Defense Logistics Agency awarded a $1,132.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune inflammatory conditions. The delivery order, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, was issued without a set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $4,843.93 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 8, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. The contract represents a single delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, valued at $10,030.26, for the supply of HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL auto-injectors. This firm fixed-price delivery order, issued on August 5, 2025, represents a competitive award with no set-aside designation and a completion date of August 6, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as the company's primary...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen for Crohn's disease and ulcerative colitis treatment at 80 milligrams. The award, made on July 21, 2025, with an ultimate completion date of July 22, 2025, utilizes firm fixed pricing with no set-aside designation. This delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,265.90 delivery order on July 18, 2025, for HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 21, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD9G1Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen injections, 80 milligrams, for the treatment of Crohn's disease, ulcerative colitis, and other health conditions. This non-competitive delivery order, valued at $4,531.80, was executed on August 7, 2025, with an ultimate completion date of August 8, 2025. The contract utilizes firm fixed pricing and represents a pediatric or specialized pharmaceutical supply requirement being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999.99 million through December 2026. This prime contract vehicle enables AmerisourceBergen to serve as a pharmaceutical prime vendor for the Defense Health Agency, military medical systems, and other federal healthcare programs worldwide. The company's extensive portfolio demonstrates its role as a critical supplier of specialty medications and medical commodities across multiple therapeutic domains to support military and veteran healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 8/7/25 |